c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia

Biomarker Research

Table 1 Percent changes (Δ-values are differences between means) in c-MYB and ESPL1/Separase transcript and protein levels under IM treatment when compared to corresponding untreated cells

Cell line, dose and period of treatment	c-MYB transcript levels^a	c-MYB protein levels^b	ESPL1 transcript levels^a	Separase protein levels^b
LAMA-84, 2.5 μM IM, 24 h	−88.8 ± 4.4, p < 0.0001	−25.7 ± 9.6, p = 0.0233	−90.3 ± 3.3, p < 0.0001	−75.8 ± 16.8, p = 0.0064
K562, 1 μM IM, 24 h	−82.4 ± 4.4, p < 0.0001	−37.1 ± 9.6, p = 0.0082	−25.0 ± 9.7, p = 0.0328	−53.1 ± 4.4, p = 0.0015
U937, 5 μM IM, 48 h	−9.1 ± 2.9, p = 0.0363	+9.8 ± 10.2, p = 0.3942	−8.1 ± 9.5, p = 0.4198	−10.5 ± 11.2, p = 0.3775

^a Δ-values [%] were calculated from at least triplicate qRT-PCR experiments and were normalized to the housekeeping gene Gus
^b Δ-values [%] are derived from at least triplicate Western blot immunostaining experiments. All protein values were normalized to Actin as loading control
Abbreviations: d days, h hours, IM imatinib; + increase, − decrease

ISSN: 2050-7771